These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 30890531)

  • 1. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.
    Alizadeh D; Wong RA; Yang X; Wang D; Pecoraro JR; Kuo CF; Aguilar B; Qi Y; Ann DK; Starr R; Urak R; Wang X; Forman SJ; Brown CE
    Cancer Immunol Res; 2019 May; 7(5):759-772. PubMed ID: 30890531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
    Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
    Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
    Mu-Mosley H; Ostermann L; Muftuoglu M; Vaidya A; Bonifant CL; Velasquez MP; Gottschalk S; Andreeff M
    Front Immunol; 2022; 13():880108. PubMed ID: 35615350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models.
    Shi H; Li A; Dai Z; Xue J; Zhao Q; Tian J; Song D; Wang H; Chen J; Zhang X; Zhou K; Wei H; Qin S
    Front Immunol; 2023; 14():1165404. PubMed ID: 37564658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
    Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rejuvenating Effector/Exhausted CAR T Cells to Stem Cell Memory-Like CAR T Cells By Resting Them in the Presence of CXCL12 and the NOTCH Ligand.
    Ando M; Kondo T; Tomisato W; Ito M; Shichino S; Srirat T; Mise-Omata S; Nakagawara K; Yoshimura A
    Cancer Res Commun; 2021 Oct; 1(1):41-55. PubMed ID: 36860911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.
    Pilipow K; Roberto A; Roederer M; Waldmann TA; Mavilio D; Lugli E
    Cancer Res; 2015 Dec; 75(24):5187-5193. PubMed ID: 26627006
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.
    Nguyen R; Doubrovina E; Mousset CM; Jin BY; Okada R; Zhang X; Clavel A; Reyes-Gonzalez JM; Dyomin V; Diaz L; Zhang L; Abbas S; Sun M; Hsieh CM; Ho M; Shern JF; Gulley JL; Hinrichs CS
    Clin Cancer Res; 2024 Apr; 30(8):1555-1566. PubMed ID: 37910044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-Generation Manufacturing Protocols Enriching T
    Arcangeli S; Falcone L; Camisa B; De Girardi F; Biondi M; Giglio F; Ciceri F; Bonini C; Bondanza A; Casucci M
    Front Immunol; 2020; 11():1217. PubMed ID: 32636841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NOTCH-FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memory-like CAR-T Cells.
    Kondo T; Ando M; Nagai N; Tomisato W; Srirat T; Liu B; Mise-Omata S; Ikeda M; Chikuma S; Nishimasu H; Nureki O; Ohmura M; Hayakawa N; Hishiki T; Uchibori R; Ozawa K; Yoshimura A
    Cancer Res; 2020 Feb; 80(3):471-483. PubMed ID: 31767627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.
    Liu L; Bi E; Ma X; Xiong W; Qian J; Ye L; Su P; Wang Q; Xiao L; Yang M; Lu Y; Yi Q
    Nat Commun; 2020 Nov; 11(1):5902. PubMed ID: 33214555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
    Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
    Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexpression of
    Xu T; Wang C; Chen X; Bai J; Wang E; Sun M
    Immunotherapy; 2022 Dec; 14(18):1457-1466. PubMed ID: 36597720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.
    Xu Y; Zhang M; Ramos CA; Durett A; Liu E; Dakhova O; Liu H; Creighton CJ; Gee AP; Heslop HE; Rooney CM; Savoldo B; Dotti G
    Blood; 2014 Jun; 123(24):3750-9. PubMed ID: 24782509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.